This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

The antibacterial property is similar to that of cefazolin, and it has good antibacterial effect on Staphylococcus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Haemophilus influenzae, etc.

After oral administration, it can form a protective film on the gastric mucosa and stimulate the gastric mucosal epithelial cells to secrete mucus, increasing the protective effect on the mucosa. In addition, it can kill Helicobacter pylori and promote the healing of gastritis.

After oral administration, it can form a protective film on the gastric mucosa and stimulate the gastric mucosal epithelial cells to secrete mucus, increasing the protective effect on the mucosa. In addition, it can kill Helicobacter pylori and promote the healing of gastritis.

The third generation of oral cephalosporins kill bacteria by inhibiting bacterial cell wall synthesis. They are stable to most beta-lactamases and have good antibacterial effects on Gram-positive cocci such as pneumococci and Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). In vitro, they also have antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate. They have poor antibacterial effects on Staphylococcus, and have no antibacterial effects on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, and Clostridium.